Your browser doesn't support javascript.
loading
Cluster analysis of long COVID in Japan and association of its trajectory of symptoms and quality of life.
Ito, Fumimaro; Terai, Hideki; Kondo, Masahiro; Takemura, Ryo; Namkoong, Ho; Asakura, Takanori; Chubachi, Shotaro; Masuzawa, Keita; Nakayama, Sohei; Suzuki, Yusuke; Hashiguchi, Mizuha; Kagyo, Junko; Shiomi, Tetsuya; Minematsu, Naoto; Manabe, Tadashi; Fukui, Takahiro; Funatsu, Yohei; Koh, Hidefumi; Masaki, Katsunori; Ohgino, Keiko; Miyata, Jun; Kawada, Ichiro; Ishii, Makoto; Sato, Yasunori; Fukunaga, Koichi.
  • Ito F; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Terai H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan hidekit926@gmail.com rtakemura@keio.jp.
  • Kondo M; Keio Cancer Center, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Japan.
  • Takemura R; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
  • Namkoong H; Graduate School of Health Management, Keio University, Kanagawa, Japan.
  • Asakura T; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan hidekit926@gmail.com rtakemura@keio.jp.
  • Chubachi S; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Masuzawa K; Department of Clinical Medicine (Laboratory of Bioregulatory Medicine), Kitasato University School of Pharmacy, Tokyo, Japan.
  • Nakayama S; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Suzuki Y; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Hashiguchi M; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Kagyo J; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Shiomi T; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Minematsu N; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Manabe T; Department of Internal Medicine, Keiyu Hospital, Kanagawa, Japan.
  • Fukui T; Department of Internal Medicine, Keiyu Hospital, Kanagawa, Japan.
  • Funatsu Y; Department of Internal Medicine, Hino Municipal Hospital, Tokyo, Japan.
  • Koh H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan.
  • Ohgino K; Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan.
  • Miyata J; Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan.
  • Kawada I; Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Sato Y; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
BMJ Open Respir Res ; 11(1)2024 02 23.
Article en En | MEDLINE | ID: mdl-38395459
ABSTRACT

BACKGROUND:

Multiple prolonged symptoms observed in patients who recovered from COVID-19 are defined as long COVID. Although diverse phenotypic combinations are possible, they remain unclear. This study aimed to perform a cluster analysis of long COVID in Japan and clarify the association between its characteristics and background factors and quality of life (QOL).

METHODS:

This multicentre prospective cohort study collected various symptoms and QOL after COVID-19 from January 2020 to February 2021. This study included 935 patients aged ≥18 years with COVID-19 at 26 participating medical facilities. Hierarchical cluster analysis was performed using 24 long COVID symptom at 3 months after diagnosis.

RESULTS:

Participants were divided into the following five clusters numerous symptoms across multiple organs (cluster 1, n=54); no or minor symptoms (cluster 2, n=546); taste and olfactory disorders (cluster 3, n=76); fatigue, psychoneurotic symptoms and dyspnoea (low prevalence of cough and sputum) (cluster 4, n=207) and fatigue and dyspnoea (high prevalence of cough and sputum) (cluster 5, n=52). Cluster 1 included elderly patients with severe symptoms, while cluster 3 included young female with mild symptoms. No significant differences were observed in the comorbidities. Cluster 1 showed the most impaired QOL, followed by clusters 4 and 5; these changes as well as the composition of symptoms were observed over 1 year.

CONCLUSIONS:

We identified patients with long COVID with diverse characteristics into five clusters. Future analysis of these different pathologies could result in individualised treatment of long COVID. TRIAL REGISTRATION NUMBER The study protocol is registered at UMIN clinical trials registry (UMIN000042299).
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Adolescent / Adult / Aged / Female / Humans País como asunto: Asia Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Adolescent / Adult / Aged / Female / Humans País como asunto: Asia Idioma: En Año: 2024 Tipo del documento: Article